331 completed, 53 terminated, 36 recruiting, 36 unknown. 518 Phase 2, 72 Phase 1, 26 Phase 3.
Follow Dermatitis: new trials by email Literature Review of Dermatitis trials Research Report on Dermatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis Ivermectin Pill - Atopic Dermatitis | Phase 2 | Withdrawn | Stanford University | 2030-12-01 | 2024-12-02 | |
| Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis EC-18, Placebo EC-18 - Atopic Dermatitis | Phase 2 | Not yet recruiting | Enzychem Lifesciences Corporation | 150 | 2027-05-01 | 2026-08-28 |
| Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome) Benralizumab 30 MG/ML [Fasenra], Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride - DRESS Syndrome | Phase 2 | Not yet recruiting | University Hospital, Lille | 96 | 2027-01-06 | 2026-05-15 |
| A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis 0.5% AR100DP1, Placebo - Dermatitis Atopic | Phase 2 | Recruiting | Arjil Pharmaceuticals LLC | 40 | 2026-10-21 | 2026-11-03 |
| Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis LT-002-158, Placebo - Atopic Dermatitis (AD) | Phase 2 | Recruiting | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | 160 | 2026-10-01 | 2026-10-26 |
| A Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis JYP0066 4% topical cream, 3% JYP0066 topical cream, 2% JYP0066 topical cream - Atopic Dermatitis (AD) | Phase 2 | Not yet recruiting | Guangzhou JOYO Pharma Co., Ltd | 160 | 2026-09-30 | 2026-09-30 |
| Superoxide Dismutase Skin Spray for the Prevention of Acute Radiation Dermatitis in Head and Neck Cancer A topical superoxide dismutase skin spray, Placebo Spray - Radiation-induced Dermatitis | Phase 2 | Recruiting | West China Hospital | 140 | 2026-09-28 | 2026-10-29 |
| PRA-216 Atopic Dermatitis Safety and Efficacy Study Active PRA-216, Placebo - Atopic Dermatitis (AD) | Phase 2 | Recruiting | Prana Therapies Inc | 39 | 2026-09-17 | 2026-10-28 |
| A Study Evaluating TRIV-573 in Atopic Dermatitis TRIV-573, Placebo - Atopic Dermatitis | Phase 2 | Recruiting | Triveni Bio | 90 | 2026-09-09 | 2026-10-28 |
| Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients Lebrikizumab - Prurigo Nodularis (PN) | Phase 2 | Not yet recruiting | University of Maryland, Baltimore | 15 | 2026-09-01 | 2026-09-03 |
| Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis HXN6005, Placebo - Health Adult Subjects, Atopic Dermatitis (AD) | Phase 1 / Phase 2 | Not yet recruiting | Helixon Biotechnology (Suzhou) Co., Ltd | 67 | 2026-09-01 | 2026-08-24 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic Dermatitis TLL-018 tablets, Placebo - Atopic Dermatitis (AD) | Phase 2 / Phase 3 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 390 | 2026-08-31 | 2026-08-25 |
| A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis ENV-294, Placebo - Atopic Dermatitis | Phase 2 | Recruiting | Enveda Therapeutics | 200 | 2026-06-29 | 2026-08-06 |
| Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis IMG-007 - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 2 | Enrolling by invitation | Inmagene LLC | 400 | 2026-06-05 | 2026-07-29 |
| A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis VC005 group, VC005 Placebo group - Atopic Dermatitis | Phase 2 | Recruiting | Jiangsu vcare pharmaceutical technology co., LTD | 120 | 2026-06-01 | 2026-07-07 |
| The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching Upadacitinib 15 MG - Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC) | Phase 2 | Not yet recruiting | RenJi Hospital | 44 | 2026-06-01 | 2026-07-01 |
| A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis Camoteskimab, Placebo - Atopic Dermatitis, Atopic | Phase 2 | Recruiting | Apollo Therapeutics Ltd | 280 | 2026-05-28 | 2026-08-28 |
| HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis HL-300, Placebo - Atopic Dermatitis | Phase 1 / Phase 2 | Recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 156 | 2026-05-26 | 2026-06-23 |
| Topical Chinese Medicine and Exosome Mechanisms for Atopic Dermatitis menthol-based hand and foot gloves, Sham menthol-based hand and foot gloves - Atopic Dermatitis (AD) | Phase 2 | Active not recruiting | Taiwan Municipal An-Nan Hospital-China Medical University | 44 | 2026-04-29 | 2026-07-09 |
| A Clinical Study to Evaluate SM17 for Atopic Dermatitis SM17 for subcutaneous injection, SM17 placebo for subcutaneous injection - Atopic Dermatitis | Phase 2 | Recruiting | SinoMab BioScience Ltd | 200 | 2026-03-31 | 2026-04-06 |
Showing 20 of 518. Sign in to see all of them.
Dermatitis, Atopic (401) · Eczema (119) · Pruritus (32) · Skin Diseases (29) · Radiodermatitis (27) · Breast Neoplasms (17) · Dermatitis, Seborrheic (13) · Hand-Foot Syndrome (13) · Stevens-Johnson Syndrome (12) · Psoriasis (10) · Immune System Diseases (9) · Dermatitis, Allergic Contact (7) · Dermatitis, Contact (6) · Food Hypersensitivity (6)
Skin and Connective Tissue Diseases (517) · Skin Diseases (489) · Skin Diseases, Eczematous (442) · Immune System Diseases (421) · Hypersensitivity (420) · Hypersensitivity, Immediate (404) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (403) · Genetic Diseases, Inborn (402) · Skin Diseases, Genetic (398) · Pathological Conditions, Signs and Symptoms (47) · Signs and Symptoms (37) · Skin Manifestations (34) · Neoplasms (30) · Chemically-Induced Disorders (28)
dupilumab (15) · Ointments (9) · nemolizumab (6) · Exercise (5) · R-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-4-methyl-2-(((2-methyl-5-quinolyl)amino)methyl)pentan-2-ol (5) · apremilast (5) · tofacitinib (5) · Triamcinolone (4) · Triamcinolone Acetonide (4) · abrocitinib (4) · difamilast (4) · lebrikizumab (4) · methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)amino)carbonyl)benzoate (4) · pimecrolimus (4) · ruxolitinib (4)
Pfizer (14) · National Institute of Allergy and Infectious Diseases (NIAID) (10) · Novartis Pharmaceuticals (10) · Regeneron Pharmaceuticals (10) · Keymed Biosciences Co.Ltd (9) · LEO Pharma (9) · Bayer (7) · Galderma R&D (7) · GlaxoSmithKline (7) · Sanofi (7) · Janssen Research & Development, LLC (6) · Aclaris Therapeutics, Inc. (5) · Allerderm (5) · DS Biopharma (5) · AbbVie (4)
United States (259) · Canada (112) · Germany (96) · Poland (72) · China (67) · Japan (49) · Australia (43) · United Kingdom (43) · Czechia (36) · Spain (35) · France (29) · Hungary (29) · South Korea (24) · Taiwan (23) · Bulgaria (19)
David Berk, MD (3) · David Zammit, Ph.D. (3) · Jianzhong Zhang (3)
PMID 25006719, PMID 39077906, PMID 16205524, PMID 16895558, PMID 17346444, PMID 17349686, PMID 18221472, PMID 18595980, PMID 18645136, PMID 19525871, PMID 20970174, PMID 21039597, PMID 21771098, PMID 21771118, PMID 21801246, PMID 22093109, PMID 22153774, PMID 22508772, PMID 22948032, PMID 23174658, PMID 23517039, PMID 23638978, PMID 23768574, PMID 23902407, PMID 23926244, PMID 24279519, PMID 24284985, PMID 24330256, PMID 24331381, PMID 24948349, PMID 25002964, PMID 25705822, PMID 25705823, PMID 26297574, PMID 26439129, PMID 26454361, PMID 26461821, PMID 26527564, PMID 26569624, PMID 26581111, PMID 26618557, PMID 26777100, PMID 26942922, PMID 27268421, PMID 27297994, PMID 28249150, PMID 28403910, PMID 28476287, PMID 28845523, PMID 29567358
2018 (12), 2025 (7), 2023 (6), 2016 (4), 2014 (3), 2015 (2), 2019 (2), 2008 (1), 2009 (1), 2017 (1), R21CA178648 (1), R33AR077495 (1), R61AR084210 (1), U01AI147462 (1), U10CA037420 (1)